tetano
Editor, Senior Moderator
Turk Thorac J
. 2022 Mar;23(2):185-191.
doi: 10.5152/TurkThoracJ.2022.0201.
COVID-19 Pneumonia After SARS-CoV-2 Vaccination with CoronaVac: A Case Series from Turkey
Mehmet Meriç Çoban[SUP] 1 [/SUP], Mehmet Nuri Yakar[SUP] 2 [/SUP], Murat Küçük[SUP] 3 [/SUP], Bişar Ergün[SUP] 3 [/SUP], Muammer Çelik[SUP] 4 [/SUP], Begüm Ergan[SUP] 5 [/SUP], Erdem Yaka[SUP] 6 [/SUP], Necati Gökmen[SUP] 2 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 is a novel viral infection that has caused a pandemic globally. Many kinds of vaccine development studies were conducted to prevent the spread and deaths. The CoronaVac is the most commonly used vaccine in Turkey. Phase 3 trials from various countries revealed that CoronaVac efficacy ranged from 50.7% to 91.25% but increased in moderate or severe cases to 100%. Additionally, it was remarkable owing to high seroconversion rates achieving up to 100%. After the vaccine campaign began in Turkey, critically ill patients continued to admit to our center's intensive care unit though they had been vaccinated with 2 doses of CoronaVac. The clinical course of these patients revealed that they are still at high risk of severe disease and death. Therefore, we aimed to share these patients' clinical characteristics and disease course, laboratory, and radiologic data.
. 2022 Mar;23(2):185-191.
doi: 10.5152/TurkThoracJ.2022.0201.
COVID-19 Pneumonia After SARS-CoV-2 Vaccination with CoronaVac: A Case Series from Turkey
Mehmet Meriç Çoban[SUP] 1 [/SUP], Mehmet Nuri Yakar[SUP] 2 [/SUP], Murat Küçük[SUP] 3 [/SUP], Bişar Ergün[SUP] 3 [/SUP], Muammer Çelik[SUP] 4 [/SUP], Begüm Ergan[SUP] 5 [/SUP], Erdem Yaka[SUP] 6 [/SUP], Necati Gökmen[SUP] 2 [/SUP]
Affiliations
- PMID: 35404251
- DOI: 10.5152/TurkThoracJ.2022.0201
Abstract
Coronavirus disease 2019 is a novel viral infection that has caused a pandemic globally. Many kinds of vaccine development studies were conducted to prevent the spread and deaths. The CoronaVac is the most commonly used vaccine in Turkey. Phase 3 trials from various countries revealed that CoronaVac efficacy ranged from 50.7% to 91.25% but increased in moderate or severe cases to 100%. Additionally, it was remarkable owing to high seroconversion rates achieving up to 100%. After the vaccine campaign began in Turkey, critically ill patients continued to admit to our center's intensive care unit though they had been vaccinated with 2 doses of CoronaVac. The clinical course of these patients revealed that they are still at high risk of severe disease and death. Therefore, we aimed to share these patients' clinical characteristics and disease course, laboratory, and radiologic data.